Participant flow

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies · Source last updated 2025-03-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Viracta (VRx)-3996: 10 mg twice daily (BID) valganciclovir: 900 mg BID

   id

   FG000

   title

   Phase 1b Dose Escalation Cohort 1

2. description

   VRx-3996: 5 mg BID valganciclovir: 450 mg BID

   id

   FG001

   title

   Phase 1b Dose Escalation Cohort 2a

3. description

   VRx-3996: 10 mg once daily (QD) valganciclovir: 450 mg BID

   id

   FG002

   title

   Phase 1b Dose Escalation Cohort 2b

4. description

   VRx-3996: 10 mg QD valganciclovir: 900 mg QD

   id

   FG003

   title

   Phase 1b Dose Escalation Cohort 2c

5. description

   VRx-3996: 20 mg QD on Days 1 to 4/week valganciclovir: 900 mg QD

   id

   FG004

   title

   Phase 1b Dose Escalation Cohort 3

6. description

   VRx-3996 recommended Phase 2 dose \[RP2D\]: 20 mg once daily \[QD\] on Days 1 to 4/week) and valganciclovir 900 mg QD

   id

   FG005

   title

   Phase 2 Dose Expansion - Capsule

7. description

   VRx-3996 recommended Phase 2 dose \[RP2D\]: 20 mg once daily \[QD\] on Days 1 to 4/week and valganciclovir 900 mg QD

   id

   FG006

   title

   Phase 2 Expansion - Tablet

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         7

      2. group Id

         FG001

         num Subjects

         5

      3. group Id

         FG002

         num Subjects

         4

      4. group Id

         FG003

         num Subjects

         4

      5. group Id

         FG004

         num Subjects

         5

      6. group Id

         FG005

         num Subjects

         30

      7. group Id

         FG006

         num Subjects

         9

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         7

      2. group Id

         FG001

         num Subjects

         5

      3. group Id

         FG002

         num Subjects

         4

      4. group Id

         FG003

         num Subjects

         4

      5. group Id

         FG004

         num Subjects

         5

      6. group Id

         FG005

         num Subjects

         30

      7. group Id

         FG006

         num Subjects

         9

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         0

      6. group Id

         FG005

         num Subjects

         0

      7. group Id

         FG006

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Starting valganciclovir dosage reductions based on creatinine clearance were allowed for participants with renal impairment.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice